Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: LA Clinical Trials Clear all

Conditions: HIV Infections, Psoriasis
Interventions: Acitretin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Zidovudine, Didanosine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Irvine, California • Washington D.C., District of Columbia • Galveston, Texas

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more

Conditions: Healthy Volunteers
Interventions: Use electronic cigarette or smoke conventional cigarette; Other
Lead sponsor: British American Tobacco (Investments) Limited; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Burbank, California

Conditions: HIV Infections
Interventions: Saquinavir, Zidovudine, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 17 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Hypotension, Shock
Interventions: Vasopressors; Drug
Lead sponsor: Francois Lamontagne; Other
Eligibility: 17 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California • Washington D.C., District of Columbia

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Interferon beta-1b, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • San Diego, California + 3 more

Conditions: Nicotine Dependence
Interventions: NJOY King 26 mg nicotine Electronic Nicotine Delivery System; Other
Lead sponsor: LA Clinical Trials; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Burbank, California

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 5 more

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: HIV Infections
Interventions: Saquinavir, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Harbor City, California • La Jolla, California • Los Angeles, California + 27 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Ro 24-7429; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Brookline, Massachusetts

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Hobson City, Alabama • Phoenix, Arizona • Paramount, California + 14 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 97
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: HIV Infections, AIDS-Associated Nephropathy
Interventions: Nelfinavir mesylate, Saquinavir, Lamivudine, Stavudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects

A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

Optimal VAsopressor titraTION Pilot Randomized Controlled Trial

A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Evaluation of Short-term Safety and Use Patterns of an Electronic Nicotine Delivery System

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease